ArticleThe Journal of pediatrics2018
Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.
Article in The Journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Opioid use and misuse in children, adolescents, and young adults with cancer: a systematic review of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Opioid limiting law and opioid prescriptions among Medicaid-enrolled survivors of childhood cancer.Journal of the National Cancer Institute · 2026Article
- Mental health service utilization in publicly insured survivors of childhood cancer: a claims-based analysis.JNCI cancer spectrum · 2025Article
- Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records.Neuro-oncology practice · 2024Article
- Mental Health Care Utilization Among Parents of Children With Cancer.JAMA network open · 2024Article
- Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States.The oncologist · 2024Article
- Utilization of cardiac tests in anthracycline-treated cancer survivors differs between young adults and children: A claims-based analysis.Cancer medicine · 2023Article
- Changes in Opioid Prescriptions and Potential Misuse and Substance Use Disorders Among Childhood Cancer Survivors Following the 2016 Opioid Prescribing Guideline.JAMA oncology · 2022Article
- Article
- Early Posttherapy Opioid Prescription, Potential Misuse, and Substance Use Disorder Among Pediatric Cancer Survivors.Journal of the National Cancer Institute · 2022Article
- Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003-2014.Journal of cancer survivorship : research and practice · 2022Article
- Use of complementary or alternative medicine and potential interactions with chronic medications among Chinese survivors of childhood cancer.Journal of cancer survivorship : research and practice · 2022Article
- Medical Financial Hardship in Survivors of Adolescent and Young Adult Cancer in the United States.Journal of the National Cancer Institute · 2021Article
- Use of Chronic Prescription Medications and Prevalence of Polypharmacy in Survivors of Childhood Cancer.Frontiers in oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo describe the patterns of prescription drug use among child and adolescent survivors of cancer in the early post-therapy period compared with matched peers without a cancer history. STUDY
designUsing the MarketScan commercial insurance claims database, we performed a retrospective cohort study identifying survivors of pediatric (0-21 years of age at diagnosis) leukemia, lymphoma, central nervous system, bone, or gonadal cancers who completed therapy from 2000 to 2011 and remained insured for 3 years post-therapy. Prescription fills during the first 3 years post-therapy were examined, categorized by drug class, and compared with age-, sex-, and region-matched individuals without cancer.
resultsWe identified 1414 survivors and 14 007 comparators. Compared with those without cancer, survivors had 1.5-4.5 times greater risk for filling opioids. Survivors of leukemia, lymphoma, central nervous system, and bone cancers had 2-5 times the risk for antidepressant and 3-7 times the risk for anxiolytic use. Survivors of leukemia, lymphoma, and bone tumors had 3-13 times the risk for angiotensin-converting enzyme inhibitors by the third year post-therapy.
conclusionCompared with peers without cancer, survivors of childhood cancer have greater rates of prescription use across many drug classes, suggesting greater medical morbidity. Survivors were more likely to use opioid, psychoactive, hormone, and cardiovascular medications. All general pediatricians and subspecialists should be aware of potentially emerging morbidities during the early post-therapy period to guide risk-based surveillance and survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.